It provided 7.1 months longer in OS than platinum-based chemotherapy in PD-L1 high-expression patients with NSCLC (Herbst et al., 2020), resulting in its approval as first-line monotherapy for adults with metastatic NSCLC whose tumors are EGFR and ALK wild-type but have PD-L1 stained ≥50% of tumor cells or PD-L1 stained tumor-infiltrating immune cells covering ≥10% of the tumor area in 2020 (FDA). The gene discussed is ALK; the disease is non-small cell lung carcinoma.